All of the "swishing and spitting" should be completed in all patients by 9/24/17 at the latest in this Phase 2 Brilacidin, Oral Mucossis (B-OM) trial.
One of the experts who frequently visits this board stated", Even though there is an approved drug, the current standard of care is still ice water, ice chips, and mild salt water. That should give you an idea of just how low the efficacy bar is for B OM against approved drugs. Yes, it is already a lock."
Another well vetted researcher on this board took the time to lay out in monetary terms the potential at hand with Brilacidin for the OM condition stating, "Kepivance, the only approved drug for OM, charges $10K per cycle, but it's hardly effective. There are about 500K patients affected by OM each year. If B-OM charges the same as Kepivance, $10K x 500K = $5B in annual sales. I think B-OM will dominate the market due to its efficacy, delivery method (oral rinse) and lack of competitions."
News 
Market Data 
Discover 
